// App-Quantinova.ai

4165 : Stable RUNX1p.(Leu56Ser) kinetics during the course of myeloid neoplasms disagree with putative RUNX1 poor prognosis status

Researchers

Presenter

  • Lena Rai

Principal Investigators

  • Sai Phyo

  • Elisabeth Nacheva

Medical Centers

  • HSL (Analytics) LLP, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

  • Myeloid neoplasms

Biomarkers

  • ETV6-RUNX1

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved